Generate Biomedicines (NASDAQ:GENB) Trading Up 4.6% - Time to Buy?

Key Points

• Generate Biomedicines shares rose 4.6% to about $16.86, although trading volume was 78% below the stock’s average daily volume. The company has a market capitalization of approximately $2.16 billion and trades at a negative P/E ratio.
• Analyst sentiment is broadly positive, with six Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $25.40.
• The company reported a quarterly loss of $0.52 per share, missing estimates by $0.04, on revenue of $6.31 million. Institutional investors—including Braidwell, which purchased about $55.4 million in shares—have recently taken new positions.

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) was up 4.6% on Monday . The company traded as high as $16.75 and last traded at $16.8550. 145,857 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 667,813 shares. The stock had previously closed at $16.12.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Morgan Stanley increased their price target on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an "overweight" rating in a research note on Thursday, May 14th. HC Wainwright boosted their price objective on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, May 8th. Wall Street Zen downgraded Generate Biomedicines from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Finally, Weiss Ratings began coverage on Generate Biomedicines in a research report on Tuesday, August 11th. They issued a "sell (d)" rating on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $25.40.

Generate Biomedicines Price Performance

The stock has a market capitalization of $2.16 billion and a PE ratio of -10.62. The business has a fifty day moving average price of $14.96.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The firm had revenue of $6.31 million for the quarter. On average, equities research analysts expect that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.

Hedge Funds Weigh In On Generate Biomedicines

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new stake in Generate Biomedicines during the 2nd quarter worth $96,000. AXQ Capital LP acquired a new position in shares of Generate Biomedicines in the 2nd quarter valued at $218,000. Braidwell LP bought a new position in shares of Generate Biomedicines in the 2nd quarter worth $55,398,000. Susquehanna International Group LLP bought a new position in shares of Generate Biomedicines in the 2nd quarter worth $196,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Generate Biomedicines during the second quarter worth $967,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source